返回 A A A Font Size Receive E-mail Alerts Press Releases

MSC CompassAnalyzer™ PSA Completes Patient Enrollment

[2017-10-10] 

Shanghai, China – MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC"), a joint venture of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), recently completed the patient enrollment for the clinical trial of its in-house developed CompassAnalyzer™ Pacing System Analyzer ("CompassAnalyzer™ PSA"). The clinical trial is the first pre-market multi-center clinical trial launched by MSC since the implementation of China's Quality Control Regulations of Clinical Trials for Medical Devices from June 1, 2016. Zhongshan Hospital of Shanghai Fudan University (principal investigator), Ruijin Hospital of Shanghai Jiao Tong University, and East Hospital of Shanghai Tongji University participated in the clinical trial and over 100 patients have been enrolled.
 
The pacing system analyzer ("PSA") is external equipment needed in pacemaker implantation for physicians to evaluate electrical parameters of pacemaker leads. In recent years, with the phase out of the imported products that used to monopolize the market, there has been no portable and easy-to-use PSA in the market for a long period. So, physicians are looking forward to the launch of the domestically made CompassAnalyzer™ PSA in the China market to meet such an urgent need. Once launched in China, CompassAnalyzer™ PSA will facilitate physicians, especially those in regional hospitals, to perform pacemaker procedures.
 
Since the establishment of MSC, it is devoted to developing and manufacturing innovative products uniquely designed for China's clinical needs. In the clinical trial of CompassAnalyzer™ PSA, MSC's R&D engineers had in-depth communication with clinicians to fully understand the clinical application and clinical needs of pacemaker treatment. MSC will continue to innovate and develop products based on China's clinical needs to offer more ideal solutions for Chinese patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:The First Case of Firehawk® in Kazakhstan Completed
[Next]:MicroPort® Orthopedics Hosts Satellite Meeting in CAS 2017